COVID-19 Update

Questions about Coronavirus? Click here

Child on bike with parents watching

Their Child’s First Bike Ride

New employee carrying dishes in coffee shop

Their First Part-Time Job

BASAGLAR prefilled KwikPen

Their First Basal Insulin

First times can be challenging.

A patient’s first experience with a basal insulin is no exception.

In patients with type 1 diabetes, BASAGLAR must be used concomitantly with short-acting insulin.1

BASAGLAR is a long-acting insulin used to control high blood sugar in adults and children with type 1 diabetes and adults with type 2 diabetes.

BASAGLAR is not recommended for the treatment of diabetic ketoacidosis.

Do not take Basaglar if you have:

  • symptoms of low blood sugar (hypoglycemia) or
  • an allergy to Basaglar or any of its ingredients.

Consider the ABCs of BASAGLAR® (insulin glargine injection) 100 units/mL


Available resources designed to be simple

And help your patients accept, start, and stay on basal insulin

BASAGLAR Savings Card

See terms and conditions.*

Backed by savings and support

*Offer good until 12/31/2020 for up to 24 prescriptions. Patient must have commercial drug insurance with insurance provider coverage for BASAGLAR to pay as little as $5 for each prescription of BASAGLAR, subject to a monthly cap of $150 and a separate $1800 maximum annual cap. Patient is responsible for any applicable taxes, fees, or amounts exceeding monthly or annual caps. This offer is invalid for patients without commercial drug insurance or those whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DOD, VA, TRICARE/CHAMPUS, or any state patient or pharmaceutical assistance program. Offer void where prohibited by law and subject to change or discontinue without notice. Card activation is required. Subject to additional terms and conditions, which can be found at


Do not reuse needles or share your Basaglar prefilled pen with other people. You or the other person can get a serious infection. This can happen even if you change the needle.

Comparable A1C reduction

BASAGLAR demonstrated noninferiority to Lantus® (insulin glargine injection) products as measured by A1C reduction in adult patients with type 2 diabetes.1,2

BASAGLAR vs Lantus products plus 2 or more OAMs (24 weeks)

  • A1C reduction from baseline
    • Noninferiority demonstrated: A1C reduction from baseline at 24 weeks1,2
    • BASAGLAR (n=376; baseline A1C: 8.35%): 1.3%
    • Lantus products (n=380; baseline A1C: 8.31%): 1.3%
    • Difference of 0.052% (95% CI -0.070 to 0.175)
    • The primary efficacy outcome was to test the noninferiority (0.4% and then 0.3% margin) of BASAGLAR to Lantus products, as measured by change in A1C from baseline to 24 weeks

Approved in the US or outside the US.

Three patients randomized to BASAGLAR did not receive study drug and were not included in the full analysis set. Observed A1C data at 24 weeks were available from 331 (88%) and 329 (87%) patients randomized to the BASAGLAR and US- or non-US-approved Lantus groups, respectively.

See full trial design information below.

Type 2 diabetes: Adverse reactions occurring in ≥5% of adult patients treated with BASAGLAR or Lantus products over 24 weeks of treatment1,3

The trial was not designed to evaluate the relative safety between BASAGLAR and Lantus products, and comparator adverse event rates are not an adequate basis for comparison of rates between the products.

Table showing adverse reactions occuring in ≥5% of adults patients with type 2 diabetes over 24 weeks

§Infections other than nasopharyngitis or upper respiratory tract infection.

||Infections were a category of treatment-emergent adverse events that were reported during the 24-week trial and included events such as influenza, urinary tract infection, bronchitis, gastroenteritis, and sinusitis. Excluded were nasopharyngitis and upper respiratory tract infection.4

Hypoglycemia was the most commonly observed adverse reaction in patients using insulin, including BASAGLAR. Hypoglycemia was defined as blood glucose ≤3.9 mmol/L (≤70 mg/dL) or a sign or symptom associated with hypoglycemia.

CI=confidence interval; OAMs=oral anti-diabetic medications.

Trial design: 24-week phase 3, randomized, double-blind trial of 756 patients with type 2 diabetes who were either insulin-naive and failed to achieve adequate glycemic control on at least 2 OAMs, or were already on Lantus products along with 2 or more OAMs with adequate or inadequate glycemic control. The primary endpoint was noninferiority of BASAGLAR to Lantus products as measured by change in A1C from baseline at 24 weeks.1,2

The starting dose for all insulin-naive patients was 10 U/day, while patients entering the study on Lantus products were randomized to either BASAGLAR or Lantus products at a dose equivalent to their prestudy Lantus products dose; BASAGLAR and Lantus products titration was patient-driven based on self-measured fasting plasma glucose with a target of ≤100 mg/dL.2

Approved in the US or outside the US.


BASAGLAR prefilled pens must never be shared between patients, even if the needle is changed. Sharing poses a risk of transmission of blood borne pathogens.

The BASAGLAR Experience

Resources designed to help patients accept, start, and stay on insulin

Patients may be hesitant to begin basal insulin. Designed to be simple, the BASAGLAR Experience resources may help address their initial concerns during the insulin negotiation phase as well as help reinforce important information at home when doing it on their own.

Indication and Important Safety Information

BASAGLAR is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.


BASAGLAR is not recommended for the treatment of diabetic ketoacidosis.



BASAGLAR is contraindicated during episodes of hypoglycemia, and in patients with hypersensitivity to insulin glargine or one of its excipients.


BASAGLAR prefilled pens must never be shared between patients, even if the needle is changed. Sharing poses a risk of transmission of blood borne pathogens.

Changes in insulin strength, manufacturer, type, injection site, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Any changes in insulin regimen should be made cautiously and only under close medical supervision, and the frequency of blood glucose monitoring should be increased. Due to reports of hypoglycemia and hyperglycemia, advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor blood glucose. For patients with type 2 diabetes, dosage adjustments of concomitant anti-diabetic products may be needed.

Hypoglycemia is the most common adverse reaction associated with insulins, including BASAGLAR. Severe hypoglycemia can cause seizures, may be life-threatening, or cause death.

Accidental mix-ups between another insulin glargine product (100 units/mL) and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors between BASAGLAR and other insulins, instruct patients to always check the insulin label before each injection.

Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including BASAGLAR. If hypersensitivity reactions occur, discontinue BASAGLAR; treat per standard of care and monitor until symptoms and signs resolve. BASAGLAR is contraindicated in patients who have had hypersensitivity reactions to insulin glargine or one of the excipients.

All insulin products, including BASAGLAR, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia if indicated.

Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin. Fluid retention may lead to or exacerbate heart failure. These patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.


Adverse reactions commonly associated with insulin glargine products (5% or greater incidence) are: hypoglycemia, allergic reactions, injection site reaction, lipodystrophy, pruritus, rash, edema, and weight gain.


Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs and symptoms of hypoglycemia may be blunted when beta-blockers, clonidine, guanethidine, and reserpine are co-administered with BASAGLAR.


For more information, please see Full Prescribing Information and Patient Information. Please see Instructions for Use.

1. BASAGLAR [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company. 2. Rosenstock J, Hollander P, Bhargava A, et al. Diabetes Obes Metab. 2015;17:734-741. 3. Data on file, Lilly USA, LLC. BAS20160408A. 4. Data on file, Lilly USA, LLC. BAS20160811B. 5. Lantus [Prescribing Information]. Bridgewater, NJ: sanofi-aventis U.S. LLC; 2018. 6. Linnebjerg H, Lam EC, Seger ME, et al. Diabetes Care. 2015;38:2226-2233. 7. Blevins TC, Dahl D, Rosenstock J, et al. Diabetes Obes Metab. 2015;17:726-733. 8. Data on file, Lilly USA, LLC. BAS20151103E. 9. Data on file, Lilly USA, LLC. BAS20160811A. 10. Gerstein HC, Yale JF, Harris SB, et al. Diabet Med. 2006;23:736-742. 11. BASAGLAR KwikPen [Instructions for Use]. Indianapolis, IN: Eli Lilly and Company. 12. Hirsch LJ, Gibney MA, Qu S, et al. Curr Med Res Opin. 2010;26(6):1531-1541. 13. Fischer MA, Stedman MR, Lii J, et al. J Gen Intern Med. 2010;25(4):284-290. 14. Data on file, Lilly USA, LLC. DOF-BV-US-0002.